ArticlePediatric cardiology2026
Valeo Stent Use for Ductal-Dependent Systemic Circulations.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our aim is to describe the experience of ductal stenting using the balloon-expandable Valeo stent in ductal-dependent systemic circulation. Outcomes assessed were procedural success, procedural survival, stent related complications, and re-intervention rates. Hybrid palliation, consisting of ductal stenting and bilateral pulmonary artery band placement, is a widely accepted alternative for stage I palliative surgery. Off-label use of stents is the norm for this procedure. The Valeo stent is one such example with minimal data on its use for ductal stenting. Retrospective data was collected for seventeen patients who underwent the hybrid procedure with ductus arteriosus stenting and pulmonary artery banding between November 2019 and September 2024. Descriptive statistics were performed. Seventeen patients underwent the hybrid procedure between November 2019 and September 2024 with a median age of 14 days (IQR 10-20 days) and median weight of 3.47 kg (IQR 3.2-4.2 kg). Fifteen patients had a single stent implanted at the time of the initial procedure and two patients required an additional stent. There were no intraoperative deaths, there was one in-hospital death. The interstage mortality was 30%, 12 out of 17 patients survived to subsequent planned procedure. The median duration to subsequent palliation was 157 days, during which no patients developed any in-stent stenosis or stent migration. The re-intervention rate was 35%. This consisted of 5 patients that required additional stents in the inter-stage period to address the ductal constriction in the pulmonary or aortic end and 1 patient that required balloon angioplasty for somatic growth. The Valeo stent can be a suitable option for ductal stenting during hybrid procedure in patients with hypoplastic left heart syndrome and other left heart obstructive lesions. It is an effective stent for maintaining ductal patency with good safety profile and a low rate of in-stent stenosis due to intimal proliferation during the inter-stage period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.